Physician profile
Michael Winters
NPI 1902880719
$4,009.27
in general payments reported to CMS, 2019-2025
19 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $531 · 2021: $785 · 2022: $851 · 2023: $413 · 2024: $369 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,661.10 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $585.29 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $575.98 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.56 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $245.92 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $122.89 | 2023-2025 | Voquezna |
| Olympus America INC. | $88.12 | 2024 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Intercept Pharmaceuticals, INC. | $75.92 | 2020-2023 | Ocaliva |
| Celgene Corporation | $30.05 | 2022 | |
| Biocon Biologics INC | $28.93 | 2024 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.11 | 2024 | Cyltezo |
| Ferring Pharmaceuticals INC. | $23.78 | 2023 | Rebyota |
| Amgen INC. | $23.48 | 2022 | |
| Aimmune Therapeutics, INC. | $23.01 | 2024 | |
| Fresenius Kabi USA, LLC | $16.10 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $13.20 | 2024 | Hyrimoz |
| Ucb, INC. | $11.26 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $6.61 | 2024 | Abc Balloons |
| Romark Laboratories, Lc | $2.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.